Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 242

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 18
Chunk 242
---
 will be relied upon when using the outputs method to recognize revenue. The Company expects to recognize the balance of the deferred revenue over the remaining period of eight years, subject to extension based on the outcome of the ongoing clinical development related to the Pediatric Indication and related patent application initiatives.
 
During the year ended December 31, 2024, the Company deferred indefinitely future material investments in the development of macimorelin for the diagnosis of CGHD. This decision is expected to result in a reduction of future product sales to Pharmanovia, and consequently, the Company recognized expected breakage of $715 in proportion to the pattern of sales.
 
For the year ended December 31, 2024, the Company recognized $845 (2023 - $nil) respectively as revenue, including the breakage amount, from the deferred revenue balance originating from the acquisition of Aeterna Zentaris Inc. (note 5).
 
Liabilities related to contracts with customers
 
The Company has recognized the following deferred revenue balances related to contracts with customers:
  Summary of deferred revenue
 
                        Current             Non-Current              Total      
--------------------------------------------------------------------------------
                       December 31, 2024                                        
                       Current             Non-Current             Total        
                       $                   $                       $            
Pharmanovia            115                 875                     990          
NK Meditech Limited    5                   39                      44           
Contract liabilities   120                 914                          1,034   

7.           Cash        
     and cash equivalents
-------------------------
  Schedule of cash and cash equivalents
 
                                             2024                   2023        
--------------------------------------------------------------------------------
                                           December 31,                         
                                                  2024                   2023   
                                           $                       $            
Cash on hand and balances with banks            16,393                  6,678   
Total                                           16,393                  6,678   
 
The Company had restricted cash equivalents amounting to $123 at December 31, 2024 (2023 - $8). These balances consist of certificates of deposit that are used as collateral for corporate credit cards and leases.
 
 
F-25
----
COSCIENS Biopharma Inc.
 Notes to Consolidated Financial Statements As of December 31, 2024 and 2023 and for the years ended December 31, 2024, 2023 and 2022 
(in thousands of US dollars, except share and per share data and where otherwise noted) 

8.           Trade        
     and other receivables
--------------------------
  Summary